epigallocatechin gallate has been researched along with Non-alcoholic Fatty Liver Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Gan, L; Yuan, J | 1 |
| James, A; Wang, K; Wang, Y | 1 |
| Berry, DL; Cheema, A; Chung, FL; Coia, H; Cruz, MI; Girgis, M; Hou, Y; Lee, Y; Ma, N; Pannkuk, E; Permaul, E; Rodriquez, O; Zhu, Z | 1 |
| Bruno, RS; Dey, P; Olmstead, BD; Sasaki, GY; Vodovotz, Y; Yu, Z | 1 |
| Ge, G; Hao, Q; Huang, J; Li, W; Liao, W; Tang, D; Wang, D; Wang, Y | 1 |
| Abunofal, O; Baig, S; Du, Y; Hicks, J; Mohan, C; Paglicawan, L; Soomro, S; Vanarsa, K | 1 |
| Ji, A; Li, J; Li, Y; Liu, Z; Wang, Y; Wu, D; Xie, Z; Zhang, Q; Zhong, P | 1 |
| Cheng, J; Jin, XL; Kim, J; Lao, WG; Lin, YG; Ong, M; Qu, XQ; Tan, Y; Xiao, L; Zhu, XQ | 1 |
| Di Giacomo, M; Ferramosca, A; Zara, V | 1 |
| Chen, C; Feng, Q; Hu, YY; Liu, L; Liu, Q | 1 |
| Gao, H; Hu, Y; Li, X; Tian, R; Wang, Y; Williams, BR; Xu, P; Yan, F; Ying, L; Zhao, Y | 1 |
| An, HM; Huang, JA; Lin, HY; Liu, ZH; Ou, XC; Wen, BB; Xiong, YF; Yang, Z; Zhang, YB; Zhu, MZ | 1 |
| Fung, ML; Ho, CT; Lau, TY; Leung, TM; Liong, EC; Nanji, AA; Tipoe, GL; Xiao, J | 1 |
| Baba, A; Kochi, T; Kubota, M; Moriwaki, H; Ohno, T; Shimizu, M; Shirakami, Y; Tanaka, T; Terakura, D; Tsurumi, H | 1 |
| Deng, YP; Gan, L; Guo, JQ; Li, H; Lu, XC; Luo, BD; Meng, ZJ; Xiong, RB; Zheng, ZW; Zou, F | 1 |
| Chen, Y; Deng, Y; Ding, Y; Qian, K; Sun, X | 1 |
| Carvalho-Silva, M; do Nascimento, CM; Gomes, LM; Lira, FS; Okuda, MH; Oyama, LM; Ribeiro, EB; Santamarina, AB; Santana, AA; Seelaender, M; Streck, EL | 1 |
3 review(s) available for epigallocatechin gallate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates.
Topics: Antioxidants; Catechin; Diabetes Mellitus, Type 2; Humans; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Obesity; Polyphenols; Tea | 2023 |
Antioxidant dietary approach in treatment of fatty liver: New insights and updates.
Topics: Animals; Anthocyanins; Antioxidants; Carotenoids; Catechin; Coumestrol; Curcumin; Energy Metabolism; Fatty Liver; Glucosinolates; Humans; Imidoesters; Isothiocyanates; Lipogenesis; Mitochondria; Non-alcoholic Fatty Liver Disease; Nutritional Sciences; Oxidative Stress; Oximes; Polyphenols; Quercetin; Resveratrol; Stilbenes; Sulfoxides; Xanthophylls | 2017 |
Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Autophagy; Body Weight; Catechin; Humans; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Receptors, LDL | 2018 |
14 other study(ies) available for epigallocatechin gallate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
[Effects of (+)-catechin and epigallocatechin gallate on alcoholic fatty liver in mice models].
Topics: Animals; Catechin; Fatty Liver, Alcoholic; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2021 |
Theaphenon E prevents fatty liver disease and increases CD4+ T cell survival in mice fed a high-fat diet.
Topics: Animals; Apoptosis; Catechin; CD4-Positive T-Lymphocytes; Cell Proliferation; Diet, Fat-Restricted; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Hepatocytes; Humans; Linoleic Acid; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity | 2021 |
Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota.
Topics: Animals; Catechin; Gastrointestinal Microbiome; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents; Tea | 2020 |
Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Camellia sinensis; Catechin; Diet, High-Fat; Dietary Supplements; Humans; Intestines; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Plant Extracts; Polyphenols | 2020 |
Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization.
Topics: Adipose Tissue; Animals; Body Weight; Catechin; Cholesterol; Diet, High-Fat; Disease Models, Animal; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size | 2021 |
Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway.
Topics: Animals; Apoptosis; Autophagy; Catechin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Humans; Male; Mice; Mitogen-Activated Protein Kinases; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2021 |
Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antioxidants; Catechin; Diet, High-Fat; Disease Models, Animal; Humans; Lipid Metabolism; Lipogenesis; Liver; Liver Function Tests; Male; Non-alcoholic Fatty Liver Disease; Phosphorylation; Polyphenols; Rats; Rats, Zucker; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Tea; Transcriptional Activation; Triglycerides; Up-Regulation; Weight Gain | 2017 |
(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease.
Topics: Animals; Atorvastatin; Catechin; Disease Models, Animal; Down-Regulation; Fibrillar Collagens; Gene Expression; Humans; Liver Cirrhosis; Male; Mice, Inbred C57BL; Multigene Family; Non-alcoholic Fatty Liver Disease | 2017 |
Coadministration of epigallocatechin-3-gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats.
Topics: Animals; Body Weight; Caffeine; Catechin; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tea | 2019 |
Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catechin; Cyclooxygenase 2; Diet, High-Fat; Down-Regulation; Fatty Liver; Female; Fibrosis; Forkhead Transcription Factors; Inflammation; Liver; Matrix Metalloproteinase 2; Nerve Tissue Proteins; NF-kappa B; Nitric Oxide Synthase Type II; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Tumor Necrosis Factor-alpha | 2014 |
Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.
Topics: Angiotensin II; Animals; Anticarcinogenic Agents; Catechin; Fatty Liver; Gene Expression; Hypertension; Interleukin-6; Lipid Peroxidation; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Peptidyl-Dipeptidase A; Precancerous Conditions; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Tumor Necrosis Factor-alpha | 2014 |
Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.
Topics: Animals; Biomarkers; Blood Glucose; Camellia sinensis; Catechin; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulysin; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plants, Medicinal; Time Factors | 2015 |
Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Catechin; Choline Deficiency; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Inflammation Mediators; Lipids; Liver; Male; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Signal Transduction; Transforming Growth Factor beta | 2015 |
Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice.
Topics: Animals; Body Weight; Catechin; Cytokines; Diet, High-Fat; Dietary Supplements; Enzymes; Glucose Tolerance Test; Insulin Resistance; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Tea | 2015 |